Impact of Current Bone Medications on Bone Density and Expected Change Values
Impact of Current Bone Medications on Bone Density and Expected Change Values
Saturday, April 25, 2026, 11:00am - 12:00pm Eastern Time (NY/USA)
Description and Objectives
This educational session will provide a practical overview of current pharmacologic options for the prevention and treatment of osteoporosis. Participants will review commonly used bone medications and gain a clear understanding of how these therapies differ in their mechanisms of action on bone remodeling. The program will also address expected changes in bone mineral density associated with various treatments, including realistic timelines for achieving clinically meaningful improvement, to support informed decision-making and patient counseling.
After attending this lecture, participants will be able to:
- List current bone medications used for osteoporosis prevention and treatment.
- Differentiate the mechanisms of action of these medications on bone.
- Describe expected bone density changes and the time intervals required to observe clinically meaningful improvement.
Handouts
All speakers were asked to provide handouts/lecture slides for registered attendees. Those that were provided for this session will be uploaded to the handouts tab and can be accessed/downloaded from that tab.
E. Michael Lewiecki, MD, FACP, FACE, CCD
Director
New Mexico Clinical Research & Osteoporosis Center, Inc.
Dr. Lewiecki is Director of New Mexico Clinical Research & Osteoporosis Center and Director of Bone Health ECHO at University of New Mexico Health Sciences Center in Albuquerque, NM. He is a consultant in osteoporosis and other metabolic bone diseases, supervisor and interpreter of bone density studies, and an educator with a special interest in the evaluation and treatment of osteoporosis and metabolic bone diseases. He has been principal investigator for many osteoporosis clinical trials and is author of over 390 publications in peer-reviewed medical journals with more than 45,000 citations, as well as books, book chapters, and online publications. He is past president of the International Society for Clinical Densitometry (ISCD) and founding president of the Osteoporosis Foundation of New Mexico (OFNM). He is program director of the annual Santa Fe Bone Symposium, the flagship activity of the OFNM. He is Review Editor for Osteoporosis International and is on the editorial board of the Journal of Clinical Densitometry. He has participated with development of ISCD Official Positions (2002, 2004, 2006, 2008, 2011, 2013, 2015, 2019, 2023), International Workshops on the Evaluation and Management of Primary Hyperparathyroidism (2009, 2014, 2022), and osteoporosis treatment guidelines of the National Osteoporosis Foundation / Bone Health & Osteoporosis Foundation (2008, 2014, 2022) and the American Association of Clinical Endocrinologists (2016, 2020), as well as with many other workshops and consensus statements in the field of metabolic bone disease. He has received national and international awards that include the 2021 “Dr. John P. Bilezikian ISCD Global Leadership Award”, and the 2021 “Lawrence G. Raisz Memorial Lecture Award” with the Bone Health & Osteoporosis Foundation, and the 2025 “Santa Fe Bone Symposium Award” in recognition of pioneering contributions to improving skeletal health. He was listed by Expertscape as the #1 osteoporosis expert in the world during the years 2011-2021. ScholarGPS currently lists him as #3 worldwide osteoporosis scholar for the previous 5 years.